AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 129.00 Decreased By ▼ -0.53 (-0.41%)
BOP 6.76 Increased By ▲ 0.08 (1.2%)
CNERGY 4.50 Decreased By ▼ -0.13 (-2.81%)
DCL 8.70 Decreased By ▼ -0.24 (-2.68%)
DFML 41.00 Decreased By ▼ -0.69 (-1.66%)
DGKC 81.30 Decreased By ▼ -2.47 (-2.95%)
FCCL 32.68 Decreased By ▼ -0.09 (-0.27%)
FFBL 74.25 Decreased By ▼ -1.22 (-1.62%)
FFL 11.75 Increased By ▲ 0.28 (2.44%)
HUBC 110.03 Decreased By ▼ -0.52 (-0.47%)
HUMNL 13.80 Decreased By ▼ -0.76 (-5.22%)
KEL 5.29 Decreased By ▼ -0.10 (-1.86%)
KOSM 7.63 Decreased By ▼ -0.77 (-9.17%)
MLCF 38.35 Decreased By ▼ -1.44 (-3.62%)
NBP 63.70 Increased By ▲ 3.41 (5.66%)
OGDC 194.88 Decreased By ▼ -4.78 (-2.39%)
PAEL 25.75 Decreased By ▼ -0.90 (-3.38%)
PIBTL 7.37 Decreased By ▼ -0.29 (-3.79%)
PPL 155.74 Decreased By ▼ -2.18 (-1.38%)
PRL 25.70 Decreased By ▼ -1.03 (-3.85%)
PTC 17.56 Decreased By ▼ -0.90 (-4.88%)
SEARL 78.71 Decreased By ▼ -3.73 (-4.52%)
TELE 7.88 Decreased By ▼ -0.43 (-5.17%)
TOMCL 33.61 Decreased By ▼ -0.90 (-2.61%)
TPLP 8.41 Decreased By ▼ -0.65 (-7.17%)
TREET 16.26 Decreased By ▼ -1.21 (-6.93%)
TRG 58.60 Decreased By ▼ -2.72 (-4.44%)
UNITY 27.51 Increased By ▲ 0.08 (0.29%)
WTL 1.41 Increased By ▲ 0.03 (2.17%)
BR100 10,450 Increased By 43.4 (0.42%)
BR30 31,209 Decreased By -504.2 (-1.59%)
KSE100 97,798 Increased By 469.8 (0.48%)
KSE30 30,481 Increased By 288.3 (0.95%)

A newly-discovered antibiotic-resistant gene is threatening to open a new front in the war against superbugs by rendering a last-resort drug impotent, experts warn. The gene's resistance to colistin, a life-saving medication which has been around for 60 years, is the latest frustration for physicians battling disease with a shrinking arsenal of antibiotics to treat a wide variety of ailments, many once easily curable.
Dubbed mcr-1, the resistance-conferring gene easily transfers between bacteria, benign or otherwise, found in humans, animals or the environment.
First identified in China last November, the gene has since been discovered in livestock, water, meat and vegetables for human consumption in several countries, and in humans infected with E.coli - one of the disease-causing bacteria it targets.
For the first time, mcr-1 has now also been found living in the gut of healthy humans, a conference of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) heard in Amsterdam this weekend.
Antibiotic crisis
"A key element for the emergence of superpathogens (superbugs, or drug-resistant germ strains) has made its way to our bodies," researcher Aycan Gundogdu of Turkey's Erciyes University told delegates.
"It is (only) a matter of time (before) the dissemination of mcr-1 gene will be prevalent in the clinic, bringing the world closer to an antibiotic crisis." Colistin has been available since 1959 to treat infections caused by Gram-negative bacteria - a category including the food-poisoning germs E-coli and Salmonella, as well as Acinetobacter which can cause pneumonia or serious blood and wound infections.
It was abandoned for human use in the 1980s due to high kidney toxicity, but is widely used in livestock farming, especially in China.
As bacteria have started to develop resistance to other, more modern drugs, colistin had to be brought back as a treatment of last resort in hospitals and clinics.
Now resistance to that too is becoming a problem.
Gundogdu and a team analysed DNA in faecal samples of individuals from China, Europe and Turkey. Of the 344 Chinese study subjects, six harboured the gene in their gut - a known major reservoir of drug resistance, the team found.
"They are healthy people. They are hosts, they are carrying this gene,", Gundogdu told AFP.
"After treatment, this water directly goes to the environmental water. And then we, the people, use this water for fishing, for many things, which means there is a circulation."
Another research team, which retrospectively tested stored E.coli and Salmonella samples from food-producing animals, said the gene has already been around in Europe for more than a decade.

Copyright Agence France-Presse, 2016

Comments

Comments are closed.